Also known as Hgb.
FDA updates PAH therapy label to include HYPERION data showing a 76% reduction in clinical worsening when added to background therapy for patients diagnosed within 12 months.
FDA cleared therapy for wAIHA in patients ≥12 previously or currently treated with corticosteroids; showed rapid hemoglobin gains and durable responses in Phase 2/3 ENERGY.
Nipocalimab 30 mg/kg produced rapid hemoglobin rises and ~3× more durable responders versus placebo at 24 weeks, with early fatigue improvement and reduced steroid use.
